In Vitro Pharmacology of Clinically Used Central Nervous System-Active Drugs as Inverse H1 Receptor Agonists

Authors:
  • MNM. W. Nicholas
    M. W. Nicholas
  • TST. T. Smith
    T. T. Smith
  • EBE. S. Burstein
    E. S. Burstein
  • UHU. Hacksell
    U. Hacksell
  • HTH. Timmerman
    H. Timmerman
  • RLR. Leurs
    R. Leurs
  • MBM. R. Brann
    M. R. Brann
  • DWD. M. Weiner
    D. M. Weiner

Abstract
The human histamine H1 receptor (H1R) is a prototypical G protein-coupled receptor and an important, well characterized target for the development of antagonists to treat allergic conditions. Many neuropsychiatric drugs are also known to potently antagonize this receptor, underlying aspects of their side effect profiles. We have used the cell-based receptor selection and amplification technology assay to further define the clinical pharmacology of the human H1R by evaluating >130 therapeutic and reference drugs for functional receptor activity. Based on this screen, we have reported on the identification of 8R-lisuride as a potent stereospecific partial H1R agonist (Mol Pharmacol65:538–549, 2004). In contrast, herein we report on a large number of varied clinical and chemical classes of drugs that are active in the central nervous system that display potent H1R inverse agonist activity. Absolute and rank order of functional potency of these clinically relevant brain-penetrating drugs may possibly be used to predict aspects of their clinical profiles, including propensity for sedation.

This publication has 41 references indexed in Scilit: